A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants with Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period

Grants and Contracts Details

StatusActive
Effective start/end date5/4/225/23/23

Funding

  • ICON Clinical Research: $14,350.00